X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3209) 3209
Publication (235) 235
Book Chapter (26) 26
Book Review (14) 14
Conference Proceeding (3) 3
Dissertation (3) 3
Magazine Article (3) 3
Newsletter (3) 3
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2648) 2648
female (1376) 1376
male (1376) 1376
oncology (1280) 1280
rhabdomyosarcoma (1273) 1273
child (1260) 1260
rhabdomyosarcoma - drug therapy (1226) 1226
index medicus (1045) 1045
child, preschool (936) 936
adolescent (873) 873
animals (664) 664
rhabdomyosarcoma - pathology (657) 657
cancer (653) 653
infant (643) 643
pediatrics (610) 610
antineoplastic combined chemotherapy protocols - therapeutic use (552) 552
adult (543) 543
chemotherapy (518) 518
children (485) 485
combined modality therapy (484) 484
rhabdomyosarcoma - therapy (430) 430
tumors (414) 414
mice (402) 402
rhabdomyosarcoma - radiotherapy (395) 395
sarcoma (394) 394
prognosis (375) 375
rhabdomyosarcoma - surgery (368) 368
cell line, tumor (344) 344
intergroup rhabdomyosarcoma (311) 311
treatment outcome (287) 287
hematology (283) 283
surgery (280) 280
antineoplastic agents - therapeutic use (264) 264
alveolar rhabdomyosarcoma (238) 238
sarcoma - drug therapy (228) 228
expression (225) 225
radiotherapy (217) 217
apoptosis (212) 212
vincristine - administration & dosage (212) 212
follow-up studies (207) 207
therapy (203) 203
care and treatment (201) 201
rhabdomyosarcoma - diagnosis (201) 201
research (199) 199
metastasis (198) 198
rhabdomyosarcoma - metabolism (198) 198
retrospective studies (196) 196
rhabdomyosarcoma - mortality (190) 190
neoplasm staging (186) 186
middle aged (183) 183
health aspects (177) 177
childhood (176) 176
cyclophosphamide - administration & dosage (176) 176
embryonal rhabdomyosarcoma (176) 176
analysis (170) 170
time factors (170) 170
neoplasm metastasis (167) 167
rats (167) 167
rhabdomyosarcoma - genetics (167) 167
dactinomycin - administration & dosage (163) 163
neoplasms - drug therapy (162) 162
dactinomycin - therapeutic use (156) 156
gene expression (156) 156
article (154) 154
cell biology (154) 154
vincristine - therapeutic use (154) 154
survival rate (148) 148
disease-free survival (145) 145
sarcoma, ewing - drug therapy (145) 145
soft tissue neoplasms - drug therapy (145) 145
rhabdomyosarcoma, embryonal - drug therapy (144) 144
diagnosis (143) 143
tumor cells, cultured (140) 140
cyclophosphamide - therapeutic use (139) 139
dose-response relationship, drug (137) 137
antineoplastic agents - pharmacology (134) 134
drug therapy, combination (134) 134
rhabdomyosarcoma, embryonal - pathology (134) 134
pathology (133) 133
soft-tissue sarcoma (129) 129
radiology, nuclear medicine & medical imaging (128) 128
apoptosis - drug effects (126) 126
xenograft model antitumor assays (126) 126
young adult (125) 125
proteins (124) 124
medicine & public health (122) 122
osteosarcoma - drug therapy (122) 122
sarcoma - pathology (120) 120
aged (119) 119
chemotherapy, adjuvant (118) 118
medicine (118) 118
survival (117) 117
doxorubicin - administration & dosage (116) 116
infant, newborn (115) 115
radiotherapy dosage (115) 115
neuroblastoma (114) 114
biochemistry & molecular biology (113) 113
growth (113) 113
neuroblastoma - drug therapy (113) 113
antineoplastic combined chemotherapy protocols - adverse effects (112) 112
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2997) 2997
German (67) 67
Japanese (54) 54
French (50) 50
Russian (16) 16
Spanish (15) 15
Polish (14) 14
Chinese (12) 12
Italian (6) 6
Hungarian (2) 2
Arabic (1) 1
Bulgarian (1) 1
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2016, Volume 67, pp. 130 - 140
Abstract Objectives Dose-finding trials are fundamental to develop novel drugs for children and adolescents with advanced cancer. It is crucial to maximise... 
Hematology, Oncology and Palliative Medicine | Innovative Therapies for Children with Cancer | Dose-finding trial | Prognostic factor | Phase I trial | Children | Adolescents | Survival | ONCOLOGY TRIALS | SCORE | VALIDATION | I CLINICAL-TRIALS | CONTEXT | PEDIATRIC PHASE-I | CENTER EXPERIENCE | ONCOLOGY | Osteosarcoma - drug therapy | Multivariate Analysis | Prognosis | Neuroectodermal Tumors, Primitive - drug therapy | Humans | Child, Preschool | Infant | Male | Neuroblastoma - mortality | Sarcoma, Ewing - mortality | Medulloblastoma - mortality | Ependymoma - drug therapy | Employment | Ependymoma - mortality | Sarcoma - mortality | Female | Rhabdomyosarcoma - drug therapy | Retrospective Studies | Child | Rhabdomyosarcoma - mortality | Schools | Osteosarcoma - mortality | Glioma - mortality | Neuroectodermal Tumors, Primitive - mortality | Europe | Proportional Hazards Models | Neoplasms - mortality | Therapies, Investigational | Survival Rate | Sarcoma - drug therapy | Neoplasms - drug therapy | Sarcoma, Ewing - drug therapy | Neuroblastoma - drug therapy | Adolescent | Medulloblastoma - drug therapy | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Clinical Trials, Phase I as Topic | Glioma - drug therapy | Care and treatment | Patient outcomes | Children's hospitals | Oncology, Experimental | Clinical trials | Research | Health aspects | Cancer
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 2, pp. 635 - 642
Purpose To report the clinical outcome and late side effect profile of proton radiotherapy in the treatment of children with parameningeal rhabdomyosarcoma... 
Radiology | Hematology, Oncology and Palliative Medicine | Conformal radiotherapy | Late effects | Proton radiotherapy | Parameningeal rhabdomyosarcoma | Pediatric | NECK RHABDOMYOSARCOMA | HEAD | INTERGROUP RHABDOMYOSARCOMA | INTERNATIONAL-SOCIETY | INTENSITY-MODULATED RADIOTHERAPY | NONMETASTATIC RHABDOMYOSARCOMA | SOFT-TISSUE | CHILDREN | CHILDHOOD-CANCER | ONCOLOGY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PEDIATRIC-ONCOLOGY | Follow-Up Studies | Protons - adverse effects | Humans | Child, Preschool | Protons - therapeutic use | Infant | Male | Radiotherapy - adverse effects | Organ Sparing Treatments - methods | Rhabdomyosarcoma - radiotherapy | Meningeal Neoplasms - drug therapy | Rhabdomyosarcoma, Alveolar - mortality | Massachusetts | Female | Rhabdomyosarcoma - drug therapy | Child | Rhabdomyosarcoma - mortality | Rhabdomyosarcoma, Alveolar - drug therapy | Rhabdomyosarcoma, Alveolar - radiotherapy | Treatment Outcome | Rhabdomyosarcoma, Embryonal - mortality | Rhabdomyosarcoma, Embryonal - drug therapy | Meningeal Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Meningeal Neoplasms - radiotherapy | Rhabdomyosarcoma, Embryonal - radiotherapy | Radiotherapy | Medical colleges | Nuclear radiation | DIAGNOSIS | PATIENTS | NEOPLASMS | FAILURES | PHOTONS | TEETH | RADIATION DOSES | CARIES | HISTOLOGY | PROTONS | SINUSES | MEDICAL RECORDS | NOSE | RADIATION DOSE UNITS | RADIOLOGY AND NUCLEAR MEDICINE | PEDIATRICS | RADIOTHERAPY | SIDE EFFECTS | COBALT | CONTROL
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2015, Volume 14, Issue 2, pp. 395 - 406
The mammalian target of rapamycin (mTOR) is a serine/ threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular... 
MAMMALIAN TARGET | SYNOVIAL SARCOMA | MESSENGER-RNA TRANSLATION | ACTIVATION | ONCOLOGY | AKT/MAMMALIAN TARGET | EMBRYONAL RHABDOMYOSARCOMA | CELL-CYCLE | COMPLEX 2 | RAPAMYCIN PATHWAY | P70 S6 KINASE | Osteosarcoma - drug therapy | Benzoxazoles - pharmacology | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Antineoplastic Agents - therapeutic use | Mechanistic Target of Rapamycin Complex 2 | Pyrimidines - chemistry | Mechanistic Target of Rapamycin Complex 1 | Multiprotein Complexes - antagonists & inhibitors | Adenosine Triphosphate - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Multiprotein Complexes - metabolism | Protein Kinase Inhibitors - chemistry | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Disease Models, Animal | Benzoxazoles - therapeutic use | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Down-Regulation - drug effects | Sarcoma - drug therapy | Sirolimus - pharmacology | Xenograft Model Antitumor Assays | Animals | Benzoxazoles - chemistry | Substrate Specificity - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Cell Line, Tumor | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | mTOR | Rapamycin | MLN0128
Journal Article
International Journal of Radiation Oncology Biology Physics, ISSN 0360-3016, 06/2012, Volume 83, Issue 2, pp. 720 - 726
Purpose: To analyze the effect of reduced-dose radiotherapy on local control in children with low-risk rhabdomyosarcoma (RMS) treated in the Children's... 
Radiotherapy | Local control | Low risk | Rhabdomyosarcoma | PARAMENINGEAL RHABDOMYOSARCOMA | INTERNATIONAL SOCIETY | INTERGROUP-RHABDOMYOSARCOMA | NONMETASTATIC RHABDOMYOSARCOMA | SURGICAL-MANAGEMENT | FAILURE | RADIATION-THERAPY | STUDY-IV | GROUP-III PATIENTS | ONCOLOGY | PATIENT | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Lymph Node Excision | Prostatic Neoplasms - radiotherapy | Age Factors | Humans | Child, Preschool | Infant | Male | Rhabdomyosarcoma, Embryonal - surgery | Neoplasm, Residual | Young Adult | Rhabdomyosarcoma, Embryonal - secondary | Treatment Failure | Adult | Female | Urogenital Neoplasms - drug therapy | Orbital Neoplasms - surgery | Child | Infant, Newborn | Orbital Neoplasms - radiotherapy | Prostatic Neoplasms - drug therapy | Rhabdomyosarcoma, Embryonal - pathology | Quality Control | Prostatic Neoplasms - pathology | Drug Administration Schedule | Prostatic Neoplasms - surgery | Head and Neck Neoplasms - drug therapy | Orbital Neoplasms - pathology | Urogenital Neoplasms - pathology | Orbital Neoplasms - drug therapy | Lymphatic Metastasis | Rhabdomyosarcoma, Embryonal - drug therapy | Tumor Burden | Head and Neck Neoplasms - pathology | Head and Neck Neoplasms - radiotherapy | Radiotherapy Dosage - standards | Urogenital Neoplasms - radiotherapy | Adolescent | Combined Modality Therapy - methods | Urogenital Neoplasms - surgery | Rhabdomyosarcoma, Embryonal - radiotherapy | Second-Look Surgery | Head and Neck Neoplasms - surgery | SURGERY | PATIENTS | NEOPLASMS | LYMPH NODES | FAILURES | RADIOLOGY AND NUCLEAR MEDICINE | ENDOXAN | RADIATION DOSES | RADIOTHERAPY | CHILDREN | CONTROL | HAZARDS
Journal Article
International Journal of Radiation Oncology Biology Physics, ISSN 0360-3016, 04/2012, Volume 82, Issue 5, pp. 1764 - 1770
Purpose: To compare the dosimetric parameters of intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) in patients with... 
Intensity-modulated radiotherapy | 3D-CRT | IMRT | Three-dimensional conformal radiotherapy | Rhabdomyosarcoma | Intermediate risk | TISSUE | CANCER | RADIATION-THERAPY | TRIAL | ONCOLOGY | NECK-RHABDOMYOSARCOMA | CARCINOMA | SURVIVORS | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Organs at Risk - radiation effects | Humans | Rhabdomyosarcoma - pathology | Male | Radiotherapy, Intensity-Modulated - adverse effects | Rhabdomyosarcoma - radiotherapy | Rhabdomyosarcoma, Alveolar - mortality | Treatment Failure | Sarcoma - mortality | Female | Rhabdomyosarcoma - drug therapy | Rhabdomyosarcoma, Alveolar - pathology | Child | Rhabdomyosarcoma - mortality | Sarcoma - radiotherapy | Rhabdomyosarcoma, Embryonal - pathology | Radiotherapy, Intensity-Modulated - mortality | Rhabdomyosarcoma, Alveolar - drug therapy | Radiotherapy, Intensity-Modulated - methods | Rhabdomyosarcoma, Alveolar - radiotherapy | Rhabdomyosarcoma, Embryonal - mortality | Rhabdomyosarcoma, Embryonal - drug therapy | Sarcoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epidemiologic Methods | Radiotherapy, Conformal - mortality | Radiotherapy, Conformal - adverse effects | Rhabdomyosarcoma, Embryonal - radiotherapy | Radiotherapy, Conformal - methods | Nuclear radiation | Analysis | Radiation | Medical care | Universities and colleges | Radiotherapy | Methods | Quality management | Index Medicus | PATIENTS | NEOPLASMS | INTEGRAL DOSES | FAILURES | TOXICITY | COMPARATIVE EVALUATIONS | CHILDREN | PLANNING | MULTIVARIATE ANALYSIS | RADIOLOGY AND NUCLEAR MEDICINE | REGRESSION ANALYSIS | RADIOTHERAPY | CONTROL | HAZARDS
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 12, pp. 2368 - 2375
Journal Article
by Aminkeng, Folefac and Bhavsar, Amit P and Visscher, Henk and Rassekh, Shahrad R and Li, Yuling and Lee, Jong W and Brunham, Liam R and Caron, Huib N and van Dalen, Elvira C and Kremer, Leontien C and van der Pal, Helena J and Amstutz, Ursula and Rieder, Michael J and Bernstein, Daniel and Carleton, Bruce C and Hayden, Michael R and Ross, Colin J. D and MacLeod, Stuart and Smith, Anne and Hildebrand, Claudette and Ghannadan, Reza and Miao, Fudan and Higginson, Michelle and Massah, Nasim and Borrie, Aienne and Hughes, Shevaun and Shaw, Kaitlyn and Dhoot, Satvir and Kowalec, Kaarina and Stortz, Jessica and Bendyshe-Walton, Tessa and Waltrip, Duncan and Bader, Rachel and Nijssen-Jordan, Cheri and Johnson, David and Verbeek, Linda and Kaczowka, Rick and Stevenson, Patti and Zhuwaki, Carnation and Grundy, Paul and Stobart, Kent and Wilson, Bev and Desai, Sunil and Spavor, Maria and Churcher, Linda and Chow, Terence and Hall, Kevin and Honcharik, Nick and Israels, Sara and Chan, Shanna and Garnham, Byron and Staub, Michelle and t Jong, Geert and Malkin, Becky and Portwine, Carol and Cranston, Amy and Koren, Gideon and Ito, Shinya and Nathan, Paul and Greenberg, Mark and Bournissen, Facundo Garcia and Inoue, Miho and Sakaguchi, Sachi and Tanaka, Toshihiro and Fujii, Hisaki and Ogawa, Mina and Ingram, Ryoko and Kamiya, Taro and Karande, Smita and Ghayoori, Sholeh and Silva, Mariana and Willing, Stephanie and Vaillancourt, Régis and Johnston, Donna and Mankoo, Herpreet and Wong, Elaine and Wilson, Brenda and O'Connor, Lauren and Hui, Caleb and Yuen, Cindy and Bussières, Jean-Francois and Lebel, Denis and Barret, Pierre and Clauson, Aurélie and Courbon, Eve and Cerruti, Léna and Jabado, Nada and Santo, Anelise Espirito and Nagy, Martine and Murray, Margaret and Boliver, Darlene and Tiller, Marilyn and Osborne, Carol-Anne and Goodyear, Lisa and Bowes, Lynette and Kean, Norma and Hand, Jack and Canadian Pharmacogenomics Network and Canadian Pharmacogenomics Network for Drug Safety Consortium and The Canadian Pharmacogenomics Network for Drug Safety Consortium
Nature genetics, ISSN 1061-4036, 2015, Volume 47, Issue 9, pp. 1079 - 1084
Journal Article
Human Pathology, ISSN 0046-8177, 2012, Volume 43, Issue 8, pp. 1300 - 1307
Journal Article
Cancer Research, ISSN 0008-5472, 05/2005, Volume 65, Issue 9, pp. 3868 - 3876
Journal Article
Cancer Research, ISSN 0008-5472, 10/2009, Volume 69, Issue 19, pp. 7662 - 7671
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e83832
Metformin, a well-known insulin-sensitizer commonly used for type 2 diabetes therapy, has recently emerged as potentially very attractive drug also in... 
BREAST-CANCER | INSULIN-RECEPTOR ISOFORM | EWINGS-SARCOMA | INDUCIBLE FACTOR | IN-VITRO | MULTIDISCIPLINARY SCIENCES | GROWTH | METASTATIC ABILITY | HUMAN OSTEOSARCOMA CELLS | AMPK ACTIVATION | P-GLYCOPROTEIN | Osteosarcoma - drug therapy | Pediatrics | Vincristine - pharmacology | Apoptosis - drug effects | Humans | Rhabdomyosarcoma - metabolism | Sarcoma, Ewing - pathology | Rhabdomyosarcoma - pathology | Bone Neoplasms - pathology | Immunoenzyme Techniques | Bone Neoplasms - metabolism | Rhabdomyosarcoma - drug therapy | Bone Neoplasms - drug therapy | Tumor Cells, Cultured | Child | Real-Time Polymerase Chain Reaction | Osteosarcoma - metabolism | Sarcoma, Ewing - metabolism | Enzyme-Linked Immunosorbent Assay | Metformin - pharmacology | RNA, Messenger - genetics | Antineoplastic Combined Chemotherapy Protocols | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Hypoglycemic Agents - pharmacology | Sarcoma, Ewing - drug therapy | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Hypoxia - physiopathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Phytogenic - pharmacology | Osteosarcoma - pathology | Type 2 diabetes | Prevention | Chemotherapy | Sarcoma | Analysis | Metformin | Drug therapy | Health aspects | Diabetes therapy | Cancer | TOR protein | Laboratories | Pathogenesis | Rhabdomyosarcoma | Oncology | Insulin-like growth factors | Metastasis | Glucose | Kinases | Cancer therapies | Ewing's sarcoma | Biomedical materials | Cell growth | Osteosarcoma | Xenografts | Biocompatibility | Medical research | Diabetes mellitus | Breast cancer | Metabolism | Insulin | Fatty acids | Vincristine | Signaling | Bone cancer | Molecular modelling | Pancreatic cancer | Hypoxia | Solid tumors | Diabetes | Tumors
Journal Article